Research and Practice in Thrombosis and Haemostasis

Titel Veröffentlichungsdatum Sprache Zitate
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts2020/11/01English16
Not all (N)SAID and done: Effects of nonsteroidal anti‐inflammatory drugs and paracetamol intake on platelets2020/01/01English16
Quantifying single‐platelet biomechanics: An outsider’s guide to biophysical methods and recent advances2020/03/01English16
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate2020/05/01English16
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors2021/02/01English16
Associations between illness beliefs, medication beliefs, anticoagulation‐related quality of life, and INR control: Insights from the Switching Study2018/07/01English16
Treatment of refractory delayed onset heparin‐induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)2017/07/01English16
Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A2019/07/01English16
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?2021/07/01English15
Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease2021/05/01English15
Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next‐generation sequencing2017/07/01English15
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern2021/08/01English15
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report2021/08/01English15
Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study2020/02/01English15
Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction2018/04/01English15
The risk of arterial thromboembolic events after cancer diagnosis2019/10/01English14
Hemostatic complications associated with ventricular assist devices2019/10/01English14
Genomics and transcriptomics of megakaryocytes and platelets: Implications for health and disease2018/10/01English14
Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes2020/02/01English14
Hemophilia gene therapy knowledge and perceptions: Results of an international survey2020/05/01English14
Caging the dragon: Research approach to COVID‐19–related thrombosis2021/02/01English14
DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples2021/02/01English14
Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients2020/10/01English14
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status2021/02/01English14
Maternal death and postpartum hemorrhage in sub‐Saharan Africa – A pilot study in metropolitan Mozambique2020/03/01English14
Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis2020/02/01English14
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM‐DVT): Methods of a prospective single‐arm management study2019/07/01English14
Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant2019/10/01English14
Direct oral anticoagulants for unusual‐site venous thromboembolism2021/02/01English14
Platelets in the neonate: Not just a small adult2022/03/01English14